The National Institute of Aging (NIA) will invest up to $53.4m over five years to spur innovation and enhance care for people suffering from Alzheimer’s disease and related dementias.
Funds will be offered in collaboration with National Institutes of Health (NIH) and will be used to test new care interventions in real-world settings.
Go deeper with GlobalData
To meet the challenges of complex care management for people with Alzheimer’s disease and related dementias (AD/ADRD) and their families, Brown University in Providence, Rhode Island will collaborate with Hebrew Senior Life, a Harvard Medical School Affiliate in Roslindale, Massachusetts.
Researchers at the new project, to be known as Imbedded Pragmatic AD/ADRD Clinical Trials (IMPACT) Collaboratory, will collaborate with other university scientists, who work on long-term care programmes.
The focus will be on developing new methods to care for people with AD/ADRC.
NIA director Richard J Hodes said: “There is a pressing need to improve care and support for people with dementia and their caregivers.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“The IMPACT Collaboratory will enable more effective, efficient teamwork research on finding better solutions for the millions of Americans affected by these devastating diseases.”
The IMPACT Collaboratory will look to further pragmatic clinical trials that are conducted in settings such as homes, hospitals, adult day centres and assisted living facilities.
It will also train the next generation of clinical trialists.
In the US, around 5.6 million people above the age of 65 have dementia, with many more suffering from other types of dementia.
Pragmatic clinical trials, unlike traditional clinical trials, use simpler study designs and test the methods in real-life scenarios at different settings.
In June this year, NIH agreed to fund clinical trials investigating the practicality and effectiveness of using genomics data as part of treatments for chronic disease such as high blood pressure, depression and chronic pain.
